Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | OGG1 | O15527 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044470 | 0.84 | MAPT (0.39) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL3044469 | 0.84 | MAPT (0.39) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL8249383 | 0.83 | MAPT (0.43) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL28780782 | 0.82 | KMT2A (0.50) | KMT2ALMNACES2CES1ALDH1A1 | |
| SCHEMBL4682 | 0.82 | HDAC1 (0.41) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL28240626 | 0.80 | CES2 (0.45) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL3703967 | 0.79 | CA1 (0.43) | MAPTKMT2AMEN1RAB9AMAPK1 | |
| SCHEMBL12465670 | 0.79 | MAPK1 (0.54) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL15897438 | 0.79 | KMT2A (0.46) | MAPTKMT2AMEN1LMNARAB9A | |
| SCHEMBL8691608 | 0.77 | L3MBTL1 (0.48) | MAPTKMT2AMEN1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782994-B1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY INC (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2025-03-20 | — | — | US | disclosed |
| CN-114716381-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114605327-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-114573510-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12220401-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| CN-114591242-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-114634447-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-113636978-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-113603645-B | Compounds useful as kinase inhibitors | 洛克索肿瘤学股份有限公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2011041461-A2 | POLYCYCLIC COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041729-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141768-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010141761-A2 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077883-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010077882-A2 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12220401-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | MAPT 3956/4885KMT2A 688/4885MEN1 2243/4885 |
| US-20100152257-A1 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | MAPT 4253/4885KMT2A 2228/4885MEN1 2756/4885 |
| US-20250090500-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | MAPT 3956/4885KMT2A 688/4885MEN1 2243/4885 |
| US-20100311799-A1 | POLYCYCLIC ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS | LPAR1, LPAR2, LPAR4 | MAPT 4533/4885KMT2A 1516/4885MEN1 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.